Therefore, our results substantiate further assessment of 2A3-CAR T-cells in the preclinical settings against CEACAM5/6-overexpressing cancers with parallel evaluation of the safety of such strategy, especially to address such issue as tissue penetration and bystander effect of 2A3-CAR T-cells or evaluate their effectiveness in the orthotopic settings. The gene discussed is CEACAM5; the disease is cancer.